GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » EPS (Diluted)

Raphael Pharmaceutical (Raphael Pharmaceutical) EPS (Diluted) : $-0.18 (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical EPS (Diluted)?

Raphael Pharmaceutical's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.18.

Raphael Pharmaceutical's EPS (Basic) for the three months ended in Mar. 2024 was $-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.18.

Raphael Pharmaceutical's EPS without NRI for the three months ended in Mar. 2024 was $-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.18.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Raphael Pharmaceutical EPS (Diluted) Historical Data

The historical data trend for Raphael Pharmaceutical's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphael Pharmaceutical EPS (Diluted) Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.05 -0.11 -0.23 -0.07

Raphael Pharmaceutical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.09 -0.03 -0.03

Competitive Comparison of Raphael Pharmaceutical's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raphael Pharmaceutical's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's PE Ratio falls into.



Raphael Pharmaceutical EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Raphael Pharmaceutical's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.284-0)/16.717
=-0.08

Raphael Pharmaceutical's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.55-0)/18.617
=-0.03

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Raphael Pharmaceutical  (OTCPK:RAPH) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Raphael Pharmaceutical EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.
Executives
Joseph Press director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo director, 10 percent owner, officer: Chief Executive Officer 4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria director, officer: Chief Technology Officer 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay director C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash director
Guy Ofir director, 10 percent owner, officer: President 40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen director, 10 percent owner, officer: Secretary Treasurer Director 51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines